The pessimism is well founded. Fundamentally the FDA has delivered a death blow to the company. If they can appeal through standard or De nova..it is there only shot. I would bet the lawfirm would try this approach even though chances of success are still not very good. So heres the scenario Dean will come out and say they plan to file an appeal and the stock will make another run. Wharton et all get out clean with profits and we get into another wash spin cycle through RSNA. Pumper reassured of new blood come back in droves.
News 
Market Data 
Discover 
AI
